Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company -- Ignore unavailable to you. Want to Upgrade?

To: david nordic who wrote (319)	6/10/2010 10:19:39 AM
From: Arthur Radley	Respond to of 507

It was clear from Robin's presentation yesterday......NKTR holds the ace cards in the deal making. IMO, AMGN isn't in a positive to NOT bump the royalty to at least 6%. For a long period of time I've felt that the next growth area in drug supply is going to be enhanced delivery. Merely look at the new drugs being developed....hardly any "new" molecules...I once thought FLML could be the solution to delivery, but more and more, NKTR is providing they have the next Gillette razor model and system.(If you get my analogy to Gillette) (:>)